Dissecting molecular mechanisms of immune microenvironment dysfunction in multiple myeloma and precursor conditions

Abstract

Multiple myeloma (MM) is a disease of clonally differentiated plasma cells. MM is almost always preceded by precursor conditions, monoclonal gammopathy of unknown significance (MGUS), and smoldering MM (SMM) through largely unknown molecular events. Genetic alterations of the malignant plasma cells play a critical role in patient clinical outcomes. Del(17p), t(4;14), and additional chromosomal alterations such as del(1p32), gain(1q) and MYC translocations are involved in active MM evolution. Interestingly, these genetic alterations appear strikingly similar in transformed plasma cell (PC) clones from MGUS, SMM, and MM stages. Recent studies show that effectors of the innate and adaptive immune response show marked dysfunction and skewing towards a tolerant environment that favors disease progression. The MM myeloid compartment is characterized by myeloid-derived suppressor cells (MDSCs), dendritic cells as well as M2-like phenotype macrophages that promote immune evasion. Major deregulations are found in the lymphoid compartment as well, with skewing towards immune tolerant Th17 and Treg and inhibition of CD8+ cytotoxic and CD4+ activated effector T cells. In summary, this review will provide an overview of the complex cross-talk between MM plasma cells and immune cells in the microenvironment and the molecular mechanisms promoting progression from precursor states to full-blown myeloma.

Keywords

Multiple myeloma / plasma cells / immune-microenvironment / immune response / immunotherapy

References

[1] Palumbo A.Multiple myeloma.N Engl J Med2011;364:1046-60

[2] American Cancer Society. Cancer facts and figures; 2022. Available from: https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2022.html [Last accessed on 16 May 2023]

[3] Braunlin M,Buchanan J,Kim C.Trends in the multiple myeloma treatment landscape and survival: a U.S. analysis using 2011-2019 oncology clinic electronic health record data.Leuk Lymphoma2021;62:377-86

[4] Bianchi G,Anderson KC.Best treatment strategies in high-risk multiple myeloma: navigating a gray area.J Clin Oncol2014;32:2125-32

[5] Lohr JG,Carter SL.Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy.Cancer Cell2014;25:91-101

[6] Ledergor G,Zada M.Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma.Nat Med2018;24:1867-76

[7] Merz M,Wang J.Deciphering spatial genomic heterogeneity at a single cell resolution in multiple myeloma.Nat Commun2022;13:807 PMCID:PMC8831582

[8] Landgren O,Pfeiffer RM.Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study.Blood2009;113:5412-7 PMCID:PMC2689042

[9] Kyle RA,Rajkumar SV.Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.Leukemia2010;24:1121-7 PMCID:PMC7020664

[10] Perrot A,Tournay E.Development and validation of a cytogenetic prognostic index predicting survival in multiple myeloma.J Clin Oncol2019;37:1657-65 PMCID:PMC6804890

[11] Bolli N,Minvielle S.Genomic patterns of progression in smoldering multiple myeloma.Nat Commun2018;9:3363 PMCID:PMC6105687

[12] Ho M,Goh CY,Zhang L.Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).Leukemia2020;34:3111-25

[13] Zavidij O,Mouhieddine TH.Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma.Nat Cancer2020;1:493-506 PMCID:PMC7785110

[14] Ramachandran IR,Pisklakova A.Myeloid-derived suppressor cells regulate growth of multiple myeloma by inhibiting T cells in bone marrow.J Immunol2013;190:3815-23 PMCID:PMC3608837

[15] Görgün GT,Anderson JL.Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans.Blood2013;121:2975-87 PMCID:PMC3624943

[16] Bronte V,Chen SH.Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards.Nat Commun2016;7:12150 PMCID:PMC4935811

[17] Giese MA,Huttenlocher A.Neutrophil plasticity in the tumor microenvironment.Blood2019;133:2159-67 PMCID:PMC6524564

[18] Rodriguez PC,Zabaleta J.Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses.Cancer Res2004;64:5839-49

[19] Darcy CJ,Piera KA.Neutrophils with myeloid derived suppressor function deplete arginine and constrain T cell function in septic shock patients.Crit Care2014;18:R163 PMCID:PMC4261583

[20] Bronte V,De Santo C.IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice.J Immunol2003;170:270-8

[21] Mazzoni A,Visintin A.Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism.J Immunol2002;168:689-95

[22] Malek E,Letterio JJ.Myeloid-derived suppressor cells: the green light for myeloma immune escape.Blood Rev2016;30:341-8 PMCID:PMC6411302

[23] Sawant A,Jules J.Myeloid-derived suppressor cells function as novel osteoclast progenitors enhancing bone loss in breast cancer.Cancer Res2013;73:672-82 PMCID:PMC3548966

[24] Zhuang J,Lwin ST.Osteoclasts in multiple myeloma are derived from Gr-1+CD11b+myeloid-derived suppressor cells.PLoS One2012;7:e48871 PMCID:PMC3500251

[25] Krejcik J,Nijhof IS.Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma.Blood2016;128:384-94 PMCID:PMC4957162

[26] Casneuf T,van de Donk NWCJ.Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab.Leukemia2021;35:573-84

[27] Kuwahara-Ota S,Steinebach C.Lenalidomide and pomalidomide potently interfere with induction of myeloid-derived suppressor cells in multiple myeloma.Br J Haematol2020;191:784-95

[28] Shaul ME.Tumour-associated neutrophils in patients with cancer.Nat Rev Clin Oncol2019;16:601-20

[29] Pillay J,Kamp VM.Immune suppression by neutrophils and granulocytic myeloid-derived suppressor cells: similarities and differences.Cell Mol Life Sci2013;70:3813-27 PMCID:PMC3781313

[30] Romano A,Simeon V.High-density neutrophils in MGUS and multiple myeloma are dysfunctional and immune-suppressive due to increased STAT3 downstream signaling.Sci Rep2020;10:1983 PMCID:PMC7005058

[31] Romano A,Cerchione C.The NLR and LMR ratio in newly diagnosed MM patients treated upfront with novel agents.Blood Cancer J2017;7:649 PMCID:PMC5802528

[32] Lee GW,Go SI.The derived neutrophil-to-lymphocyte ratio is an independent prognostic factor in transplantation ineligible patients with multiple myeloma.Acta Haematol2018;140:146-56

[33] Perez C,Zabaleta A.Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma.Blood2020;136:199-209

[34] Mantovani A,Locati M,Sica A.Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes.Trends Immunol2002;23:549-55

[35] Wu K,Li X.Redefining tumor-associated macrophage subpopulations and functions in the tumor microenvironment.Front Immunol2020;11:1731 PMCID:PMC7417513

[36] Kim J,Dollar BA.Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells.Br J Haematol2012;158:336-46 PMCID:PMC3395762

[37] Zheng Y,Wang S.Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis.Blood2009;114:3625-8 PMCID:PMC2766678

[38] Chen X,Zhang W.Prognostic value of diametrically polarized tumor-associated macrophages in multiple myeloma.Oncotarget2017;8:112685-96 PMCID:PMC5762541

[39] Zheng Y,Qian J.PSGL-1/selectin and ICAM-1/CD18 interactions are involved in macrophage-induced drug resistance in myeloma.Leukemia2013;27:702-10 PMCID:PMC3652581

[40] Hope C,Heninger E.TPL2 kinase regulates the inflammatory milieu of the myeloma niche.Blood2014;123:3305-15 PMCID:PMC4046426

[41] Storti P,Donofrio G.Hypoxia-inducible factor (HIF)-1α suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction.Leukemia2013;27:1697-706

[42] Rao L,Leone P.HB-EGF-EGFR signaling in bone marrow endothelial cells mediates angiogenesis associated with multiple myeloma.Cancers2020;12:173 PMCID:PMC7017291

[43] Filippi I,Aldinucci C.Different adaptive responses to hypoxia in normal and multiple myeloma endothelial cells.Cell Physiol Biochem2018;46:203-12

[44] Scavelli C,Cirulli T.Vasculogenic mimicry by bone marrow macrophages in patients with multiple myeloma.Oncogene2008;27:663-74

[45] Podar K.The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications.Blood2005;105:1383-95

[46] Somlo G,Bellamy W.Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma: a California cancer consortium trial.Br J Haematol2011;154:533-5 PMCID:PMC3272081

[47] White D,Bhaskar B,Wamstad K.Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma.Cancer2013;119:339-47

[48] Beyar-Katz O,Reiner-Benaim A.Proinflammatory macrophages promote multiple myeloma resistance to bortezomib therapy.Mol Cancer Res2019;17:2331-40

[49] Mougiakakos D,Böttcher M.The IKZF1-IRF4/IRF5 axis controls polarization of myeloma-associated macrophages.Cancer Immunol Res2021;9:265-78

[50] Krönke J,Narla A.Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells.Science2014;343:301-5 PMCID:PMC4077049

[51] Wang Q,Li R.Therapeutic effects of CSF1R-blocking antibodies in multiple myeloma.Leukemia2018;32:176-83 PMCID:PMC5927777

[52] Brown JM,Strober S.The promise of targeting macrophages in cancer therapy.Clin Cancer Res2017;23:3241-50 PMCID:PMC5529121

[53] Gutiérrez-González A,Samaniego R.Evaluation of the potential therapeutic benefits of macrophage reprogramming in multiple myeloma.Blood2016;128:2241-52

[54] Kim D,Willingham SB,Wernig G.Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells.Leukemia2012;26:2538-45

[55] Chen H,Sanchez E.JAK1/2 pathway inhibition suppresses M2 polarization and overcomes resistance of myeloma to lenalidomide by reducing TRIB1, MUC1, CD44, CXCL12, and CXCR4 expression.Br J Haematol2020;188:283-94

[56] Steinman RM.Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution.J Exp Med1973;137:1142-62 PMCID:PMC2139237

[57] Rossi M.Human dendritic cells: potent antigen-presenting cells at the crossroads of innate and adaptive immunity.J Immunol2005;175:1373-81

[58] Joffre OP,Savina A.Cross-presentation by dendritic cells.Nat Rev Immunol2012;12:557-69

[59] Hideshima T,Tonon G,Anderson KC.Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets.Nat Rev Cancer2007;7:585-98

[60] Ratta M,Curti A.Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6.Blood2002;100:230-7

[61] Yang DH,Jin CJ.The dysfunction and abnormal signaling pathway of dendritic cells loaded by tumor antigen can be overcome by neutralizing VEGF in multiple myeloma.Leuk Res2009;33:665-70

[62] Chauhan D,Brahmandam M.Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target.Cancer Cell2009;16:309-23 PMCID:PMC2762396

[63] Moser-Katz T,Dhodapkar MV,Boise LH.Game of bones: how myeloma manipulates its microenvironment.Front Oncol2020;10:625199 PMCID:PMC7900622

[64] Leone P,Frassanito MA.Dendritic cells accumulate in the bone marrow of myeloma patients where they protect tumor plasma cells from CD8+ T-cell killing.Blood2015;126:1443-51 PMCID:PMC4592278

[65] Ray A,Song Y.Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells.Leukemia2015;29:1441-4 PMCID:PMC5703039

[66] Talluri S,Buon L.Dysregulated APOBEC3G causes DNA damage and promotes genomic instability in multiple myeloma.Blood Cancer J2021;11:166 PMCID:PMC8501035

[67] Koduru S,Strowig T.Dendritic cell-mediated activation-induced cytidine deaminase (AID)-dependent induction of genomic instability in human myeloma.Blood2012;119:2302-9 PMCID:PMC3311257

[68] Prabhala RH,Pelluru D.Targeting IL-17A in multiple myeloma: a potential novel therapeutic approach in myeloma.Leukemia2016;30:379-89 PMCID:PMC4740263

[69] Murray ME,Nair JR.CD28-mediated pro-survival signaling induces chemotherapeutic resistance in multiple myeloma.Blood2014;123:3770-9 PMCID:PMC4055924

[70] Stocker N,Ricard L.Daratumumab prevents programmed death ligand-1 expression on antigen-presenting cells in de novo multiple myeloma.Cancer Med2020;9:2077-84 PMCID:PMC7064026

[71] Bailur JK,Doxie DB.Early alterations in stem-like/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy.JCI Insight2019;5:127807 PMCID:PMC6629164

[72] Feyler S,Jarmin S.CD4+CD25+FoxP3+regulatory T cells are increased whilst CD3+CD4−CD8−αβTCR+Double Negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden.Br J Haematol2009;144:686-95

[73] Fontenot JD,Rudensky AY.Foxp3 programs the development and function of CD4+CD25+ regulatory T cells.Nat Immunol2003;4:330-6

[74] Vignali DA,Workman CJ.How regulatory T cells work.Nat Rev Immunol2008;8:523-32 PMCID:PMC2665249

[75] Giannopoulos K,Hus I.The frequency of T regulatory cells modulates the survival of multiple myeloma patients: detailed characterisation of immune status in multiple myeloma.Br J Cancer2012;106:546-52 PMCID:PMC3273338

[76] Dahlhoff J,Steinfatt T.Transient regulatory T-cell targeting triggers immune control of multiple myeloma and prevents disease progression.Leukemia2022;36:790-800 PMCID:PMC8885410

[77] Feyler S,Parrish C.Tumour cell generation of inducible regulatory T-cells in multiple myeloma is contact-dependent and antigen-presenting cell-independent.PLoS One2012;7:e35981 PMCID:PMC3362588

[78] Tamura H,Yamashita T.Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma.Leukemia2013;27:464-72

[79] Yousef S,Steinbach M.Immunomodulatory molecule PD-L1 is expressed on malignant plasma cells and myeloma-propagating pre-plasma cells in the bone marrow of multiple myeloma patients.Blood Cancer J2015;5:e285 PMCID:PMC4382668

[80] Liu J,Wolowiec D.Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway.Blood2007;110:296-304

[81] Tai YT,Xing L.APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications.Leukemia2019;33:426-38 PMCID:PMC6367000

[82] Tai YT,An G.APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment.Blood2016;127:3225-36 PMCID:PMC4920023

[83] Scott GB,Parrish C,Cook G.Downregulation of myeloma-induced ICOS-L and regulatory T cell generation by lenalidomide and dexamethasone therapy.Cell Immunol2015;297:1-9

[84] Hadjiaggelidou C,Terpos E.Evaluation of regulatory T cells (Tregs) alterations in patients with multiple myeloma treated with bortezomib or lenalidomide plus dexamethasone: correlations with treatment outcome.Ann Hematol2019;98:1457-66

[85] Dosani T,Maric I.The cellular immune system in myelomagenesis: NK cells and T cells in the development of MM and their uses in immunotherapies.Blood Cancer J2015;5:e321 PMCID:PMC4526775

[86] Favaloro J,Aklilu E.Myeloma skews regulatory T and pro-inflammatory T helper 17 cell balance in favor of a suppressive state.Leuk Lymphoma2014;55:1090-8

[87] Shen CJ,Liu YX.Increased numbers of T helper 17 cells and the correlation with clinicopathological characteristics in multiple myeloma.J Int Med Res2012;40:556-64

[88] Noonan K,Anderson J,Roodman GD.A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma.Blood2010;116:3554-63 PMCID:PMC4017298

[89] Rossi M,Botta C.miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma.Leukemia2021;35:823-34

[90] Suen H,Yang S.Multiple myeloma causes clonal T-cell immunosenescence: identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade.Leukemia2016;30:1716-24

[91] Racanelli V,Frassanito MA.Alterations in the antigen processing-presenting machinery of transformed plasma cells are associated with reduced recognition by CD8+ T cells and characterize the progression of MGUS to multiple myeloma.Blood2010;115:1185-93 PMCID:PMC2826230

[92] Zelle-Rieser C,Biedermann R.T cells in multiple myeloma display features of exhaustion and senescence at the tumor site.J Hematol Oncol2016;9:116 PMCID:PMC5093947

[93] Dhodapkar MV,Olson K.T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells.Proc Natl Acad Sci USA2002;99:13009-13 PMCID:PMC130577

[94] Wen YJ,Tricot G,Yi Q.Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy.Blood2002;99:3280-5

[95] Guillerey C,Vuckovic S,Smyth MJ.Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies.Cell Mol Life Sci2016;73:1569-89

[96] Eltzschig HK,Robson SC.Purinergic signaling during inflammation.N Engl J Med2012;367:2322-33 PMCID:PMC3675791

[97] Deaglio S,Gao W.Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression.J Exp Med2007;204:1257-65 PMCID:PMC2118603

[98] Horenstein AL,Toscani D.Adenosine generated in the bone marrow niche through a CD38-Mediated pathway correlates with progression of human myeloma.Mol Med2016;22:694-704 PMCID:PMC5135080

[99] Yang R,Misund K.Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade.J Immunother Cancer2020;8:e000610 PMCID:PMC7239696

[100] Bonello F,Moscvin M,Boccadoro M.CD38 as an immunotherapeutic target in multiple myeloma.Expert Opin Biol Ther2018;18:1209-21

[101] Mateos MV,Schjesvold F.Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.Lancet Haematol2019;6:e459-69

[102] Usmani SZ,Oriol A.Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial.Lancet Haematol2019;6:e448-58

[103] Guillerey C,Carrié N.TIGIT immune checkpoint blockade restores CD8⁺ T-cell immunity against multiple myeloma.Blood2018;132:1689-94

[104] Lozano E,Díaz T.Nectin-2 expression on malignant plasma cells is associated with better response to TIGIT blockade in multiple myeloma.Clin Cancer Res2020;26:4688-98

[105] Minnie SA,Gartlan KH.Myeloma escape after stem cell transplantation is a consequence of T-cell exhaustion and is prevented by TIGIT blockade.Blood2018;132:1675-88

[106] García-Sanz R,Orfão A.Analysis of natural killer-associated antigens in peripheral blood and bone marrow of multiple myeloma patients and prognostic implications.Br J Haematol1996;93:81-8

[107] Pessoa de Magalhães RJ,Paiva B.Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry.Haematologica2013;98:79-86 PMCID:PMC3533663

[108] Schütt P,Stellberg W.Immune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infections.Leuk Lymphoma2006;47:1570-82

[109] Fauriat C,Olive D.Impaired activating receptor expression pattern in natural killer cells from patients with multiple myeloma.Leukemia2006;20:732-3

[110] Jurisic V,Konjevic G,Colovic M.Clinical stage-depending decrease of NK cell activity in multiple myeloma patients.Med Oncol2007;24:312-7

[111] Botta C,Martino EA.Mechanisms of immune evasion in multiple myeloma: open questions and therapeutic opportunities.Cancers2021;13:3213 PMCID:PMC8268448

[112] Bedel R,Grandclement C.Novel role for STAT3 in transcriptional regulation of NK immune cell targeting receptor MICA on cancer cells.Cancer Res2011;71:1615-26

[113] Jinushi M,Munshi NC.MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma.Proc Natl Acad Sci USA2008;105:1285-90 PMCID:PMC2234130

[114] El-Sherbiny YM,Holmes TD.The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells.Cancer Res2007;67:8444-9

[115] Fisher DT,Evans SS.The two faces of IL-6 in the tumor microenvironment.Semin Immunol2014;26:38-47 PMCID:PMC3970580

[116] Cifaldi L,Caiello I.Inhibition of natural killer cell cytotoxicity by interleukin-6: implications for the pathogenesis of macrophage activation syndrome.Arthritis Rheumatol2015;67:3037-46

[117] Beldi-Ferchiou A,Dogniaux S.PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma.Oncotarget2016;7:72961-77 PMCID:PMC5341956

[118] Lesokhin AM,Armand P.Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study.J Clin Oncol2016;34:2698-704

[119] Shah N,McCarty J.Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma.Br J Haematol2017;177:457-66 PMCID:PMC5856008

[120] Shah N,Li L.Phase II study of ex vivo expanded cord blood natural killer cells for multiple myeloma.J Clin Oncol2018;36:8006-8006

[121] Romee R,Leong JW.Cytokine activation induces human memory-like NK cells.Blood2012;120:4751-60 PMCID:PMC3520618

[122] Ho M,Patel A.Role of the bone marrow milieu in multiple myeloma progression and therapeutic resistance.Clin Lymphoma Myeloma Leuk2020;20:e752-68

[123] Bianchi G.Pathogenesis beyond the cancer clone(s) in multiple myeloma.Blood2015;125:3049-58 PMCID:PMC4432002

[124] de Jong MME,Papazian N.The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape.Nat Immunol2021;22:769-80

[125] Abe M,Wilde J.Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion.Blood2004;104:2484-91

[126] An G,Feng X.Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication.Blood2016;128:1590-603 PMCID:PMC5034739

[127] Giuliani N,Sala R.Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease.Blood2002;100:4615-21

[128] Giuliani N,Tagliaferri S.Interleukin-3 (IL-3) is overexpressed by T lymphocytes in multiple myeloma patients.Blood2006;107:841-2

[129] Chen T,Bianchi G.Exosomes in the pathogenesis and treatment of multiple myeloma in the context of the bone marrow microenvironment.Front Oncol2020;10:608815 PMCID:PMC7674795

[130] Théry C,Segura E.Membrane vesicles as conveyors of immune responses.Nat Rev Immunol2009;9:581-93

[131] Niel G, D'Angelo G, Raposo G. Shedding light on the cell biology of extracellular vesicles.Nat Rev Mol Cell Biol2018;19:213-28

[132] Colombo M,Théry C.Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles.Annu Rev Cell Dev Biol2014;30:255-89

[133] Peinado H,Lyden D.The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts.Semin Cancer Biol2011;21:139-46

[134] Ratajczak J,Hayek F,Ratajczak MZ.Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication.Leukemia2006;20:1487-95

[135] Lemaire M,De Bruyne E,Menu E.The microenvironment and molecular biology of the multiple myeloma tumor. Adv Cancer Res 2011;110.

[136] Boyiadzis M.The emerging roles of tumor-derived exosomes in hematological malignancies.Leukemia2017;31:1259-68

[137] Moloudizargari M,Asghari MH,Neagoe IB.The emerging role of exosomes in multiple myeloma.Blood Rev2019;38:100595

[138] Li M,Wang Y,Zhang Y.Potential therapeutic roles of exosomes in multiple myeloma: a systematic review.J Cancer2019;10:6154-60 PMCID:PMC6856585

[139] Roccaro AM,Maiso P.BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression.J Clin Invest2013;123:1542-55 PMCID:PMC3613927

[140] Xu H,Song S.Exosome-transmitted PSMA3 and PSMA3-AS1 promote proteasome inhibitor resistance in multiple myeloma.Clin Cancer Res2019;25:1923-35

[141] Ho M,Liu J.Targeting histone deacetylase 3 (HDAC3) in the bone marrow microenvironment inhibits multiple myeloma proliferation by modulating exosomes and IL-6 trans-signaling.Leukemia2020;34:196-209 PMCID:PMC6883144

[142] Raimondi L,Giavaresi G.Non-coding RNAs in multiple myeloma bone disease pathophysiology.Noncoding RNA2020;6:37 PMCID:PMC7549375

[143] Morelli E,Rocca R.The non-coding RNA landscape of plasma cell dyscrasias.Cancers2020;12:320 PMCID:PMC7072200

[144] Li B,Han H.Exosome-mediated transfer of lncRUNX2-AS1 from multiple myeloma cells to MSCs contributes to osteogenesis.Oncogene2018;37:5508-19

[145] Raimondo S,Vicario E.Multiple myeloma-derived exosomes are enriched of amphiregulin (AREG) and activate the epidermal growth factor pathway in the bone microenvironment leading to osteoclastogenesis.J Hematol Oncol2019;12:2 PMCID:PMC6325886

[146] Raimondo S,Conigliaro A.Extracellular vesicle microRNAs contribute to the osteogenic inhibition of mesenchymal stem cells in multiple myeloma.Cancers2020;12:449 PMCID:PMC7072478

[147] Liu Z,Li Y.Multiple myeloma-derived exosomes inhibit osteoblastic differentiation and improve IL-6 secretion of BMSCs from multiple myeloma.J Investig Med2020;68:45-51 PMCID:PMC6996099

[148] Liu R,Foltz SM.Co-evolution of tumor and immune cells during progression of multiple myeloma.Nat Commun2021;12:2559 PMCID:PMC8105337

[149] Calcinotto A,Ria R.Modifications of the mouse bone marrow microenvironment favor angiogenesis and correlate with disease progression from asymptomatic to symptomatic multiple myeloma.Oncoimmunology2015;4:e1008850 PMCID:PMC4485787

[150] Hofmann JN,Landy R.A prospective study of circulating chemokines and angiogenesis markers and risk of multiple myeloma and its precursor.JNCI Cancer Spectr2020;4:pkz104 PMCID:PMC7083234

[151] Knight A,Kralova R.Plasmacytoid dendritic cells in patients with MGUS and multiple myeloma.J Clin Med2021;10:3717 PMCID:PMC8396926

[152] Dhodapkar MV,Osman K.Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy.J Exp Med2003;198:1753-7 PMCID:PMC2194131

[153] Calcinotto A,Chesi M.Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression.Nat Commun2018;9:4832 PMCID:PMC6277390

[154] Bernal M,Jiménez P.Changes in activatory and inhibitory natural killer (NK) receptors may induce progression to multiple myeloma: implications for tumor evasion of T and NK cells.Hum Immunol2009;70:854-7

[155] Bernardini G,Santoni A.Differential chemotactic receptor requirements for NK cell subset trafficking into bone marrow.Front Immunol2013;4:12 PMCID:PMC3558687

[156] Ponzetta A,Antonangeli F.Multiple myeloma impairs bone marrow localization of effector natural killer cells by altering the chemokine microenvironment.Cancer Res2015;75:4766-77

[157] Bobin A.Recent advances in the treatment of multiple myeloma: a brief review.Fac Rev2022;11:28 PMCID:PMC9523543

[158] Munshi NC,Shah N.Idecabtagene vicleucel in relapsed and refractory multiple myeloma.N Engl J Med2021;384:705-16

[159] Anderson LD Jr.Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma.Future Oncol2022;18:277-89

[160] Rodriguez-Otero P,Arnulf B.Ide-cel or standard regimens in relapsed and refractory multiple myeloma.N Engl J Med2023;388:1002-14

[161] Martin T,Berdeja JG.Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up.J Clin Oncol2023;41:1265-74 PMCID:PMC9937098

[162] Van Oekelen O,Mouhieddine TH.Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy.Blood2023;141:756-65 PMCID:PMC10082354

[163] Rafiq S,Brentjens RJ.Engineering strategies to overcome the current roadblocks in CAR T cell therapy.Nat Rev Clin Oncol2020;17:147-67 PMCID:PMC7223338

[164] Teoh PJ.CAR T-cell therapy in multiple myeloma: more room for improvement.Blood Cancer J2021;11:84 PMCID:PMC8085238

[165] Ho M,Yi D,Bianchi G.Treating multiple myeloma in the context of the bone marrow microenvironment.Curr Oncol2022;29:8975-9005 PMCID:PMC9689284

[166] Tian Z,Zhang Y.Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies.J Hematol Oncol2021;14:75 PMCID:PMC8091790

[167] Subklewe M.BiTEs better than CAR T cells.Blood Adv2021;5:607-12 PMCID:PMC7839370

[168] Moreau P,Goldberg JD.Teclistamab in relapsed or refractory multiple myeloma.N Engl J Med2022;387:1721-3

[169] Bahlis NJ,Costello C.Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM).J Clin Oncol2021;39:8006-8006

[170] Jakubowiak AJ,Raje NS.Elranatamab, a BCMA-targeted T-cell redirecting immunotherapy, for patients with relapsed or refractory multiple myeloma: updated results from MagnetisMM-1.J Clin Oncol2022;40:8014-8014

[171] Verkleij CPM,van Duin M.Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma.Blood Adv2021;5:2196-215 PMCID:PMC8095149

[172] Pillarisetti K,Mendonça M.A T-cell-redirecting bispecific G-protein-coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma.Blood2020;135:1232-43 PMCID:PMC7146017

[173] Doucey M,Estoppey C.ISB 1342: a first-in-class CD38 T cell engager for the treatment of relapsed refractory multiple myeloma.J Clin Oncol2021;39:8044-8044

[174] Lonial S,Badros A.Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study.Cancer2021;127:4198-212 PMCID:PMC8597112

[175] Ailawadhi S,Vescio RA.A phase I study to assess the safety and pharmacokinetics of single-agent lorvotuzumab mertansine (IMGN901) in patients with relapsed and/or refractory CD-56-positive multiple myeloma.Clin Lymphoma Myeloma Leuk2019;19:29-34 PMCID:PMC9059793

[176] Kelly KR,Siegel DS.Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study.Lancet Haematol2021;8:e794-807

[177] Fionda C,Zingoni A.The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma.Oncotarget2015;6:23609-30 PMCID:PMC4695140

[178] Feng X,Acharya C.Targeting CD38 suppresses induction and function of T regulatory cells to mitigate immunosuppression in multiple myeloma.Clin Cancer Res2017;23:4290-300 PMCID:PMC5540790

[179] Lonial S,Usmani SZ.Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.Lancet2016;387:1551-60

[180] Mateos MV,Hungria V.Daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in patients with previously treated multiple myeloma: three-year follow-up of CASTOR.Clin Lymphoma Myeloma Leuk2020;20:509-18

[181] Bahlis NJ,White DJ.Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study.Leukemia2020;34:1875-84 PMCID:PMC7326710

[182] Mateos MV,Cavo M.Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.N Engl J Med2018;378:518-28

[183] Facon T,Plesner T.Daratumumab plus lenalidomide and dexamethasone for untreated myeloma.N Engl J Med2019;380:2104-15 PMCID:PMC10045721

[184] Moreau P,Hulin C.Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.Lancet2019;394:29-38

[185] Dimopoulos MA,Boccadoro M.Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial.Lancet Oncol2021;22:801-12

[186] Attal M,Rajkumar SV.Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.Lancet2019;394:2096-107

[187] Moreau P,Mikhael J.Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial.Lancet2021;397:2361-71

[188] Campbell KS,Pazina T.Mechanisms of NK cell activation and clinical activity of the therapeutic SLAMF7 antibody, elotuzumab in multiple myeloma.Front Immunol2018;9:2551 PMCID:PMC6230619

[189] Awwad MHS,Bruns H.Selective elimination of immunosuppressive T cells in patients with multiple myeloma.Leukemia2021;35:2602-15 PMCID:PMC8410603

[190] Lonial S,Palumbo A.Elotuzumab therapy for relapsed or refractory multiple myeloma.N Engl J Med2015;373:621-31

[191] Dimopoulos MA,Grosicki S.Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma.N Engl J Med2018;379:1811-22

[192] Osman K,Parekh S.Phase 1 study of elotuzumab in combination with autologous stem cell transplantation and lenalidomide maintenance for multiple myeloma. Biol Blood Marrow Transplant 2018;24:S49-50.

[193] Rossi M,Correale P,Tagliaferri P.Immunologic microenvironment and personalized treatment in multiple myeloma.Expert Opin Biol Ther2013;13 Suppl 1:S83-93